Cite
HARVARD Citation
Matulonis, U. et al. (2016). Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 122 (12), pp. 1844-1852. [Online].